Autologous dendritic cell immunotherapy - DiaVacs

Drug Profile

Autologous dendritic cell immunotherapy - DiaVacs

Alternative Names: Dendritic cell-based diabetes therapy - DiaVacs; DV-100; DV-200; DV0100; iDC

Latest Information Update: 11 Dec 2015

Price : $50

At a glance

  • Originator DiaVacs
  • Class Antihyperglycaemics; Antisense DNA; Dendritic cell vaccines
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Type 1 diabetes mellitus
  • New Molecular Entity No

Highest Development Phases

  • Phase II Type 1 diabetes mellitus

Most Recent Events

  • 11 Dec 2015 Preclinical trials in Type-1 diabetes mellitus in USA (SC)
  • 06 Jan 2014 Phase-II clinical trials in Type-1 diabetes mellitus in USA (Intradermal)
  • 06 Jan 2014 DV 0100 receives Orphan Drug status for Type-1 diabetes mellitus in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top